Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Nagaraju, Shankar P ^a   Cohn, Adam ^b   Akbari, Ayub ^c   Davis, Janet L ^d   Zimmerman, Deborah L ^c  

^a KASTURBA MEDICAL COLLEGE   (India)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d Division of Nephrology   (Canada)

Author keywords

Anemia; Chronic kidney disease; Iron

Indexed keywords

FERRITIN; HEME IRON POLYPEPTIDE; HEMOGLOBIN; IRON; IRON DERIVATIVE; IRON SACCHARATE; TRANSFERRIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BLOATING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL STUDY; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DYSPEPSIA; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; MALE; MUSCLE CRAMP; NAUSEA; NON DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; DIALYSIS; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84875075938     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-64     Document Type: Article

References (39)

1. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K, J Am Soc Nephrol 2006 17 1181 91 10.1681/ASN.2005090997 16565261
2. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third National Health and Nutrition examination survey. Hsu CY, McCulloch CE, Curhan GC, J Am Soc Nephrol 2002 13 504 10 11805181 (Pubitemid 34106294)
3. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O, Am J Kidney Dis 1999 34 125 34 10.1016/S0272-6386(99)70118-6 10401026 (Pubitemid 29318806)
4. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW, N Engl J Med 1987 316 73 78 10.1056/NEJM198701083160203 3537801 (Pubitemid 17052741)
5. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD, BMJ 1989 299 157 58 10.1136/bmj.299.6692.157 2504356 (Pubitemid 19186661)
6. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M, Am J Kidney Dis 1996 27 234 8 10.1016/S0272-6386(96)90546-6 8659499 (Pubitemid 26055136)
7. R-HuEPO hyporesponsiveness-who and why? Danielson B, Nephrol Dial Transplant 1995 10 suppl 2 69 S73
8. Iron status and hemoglobin level in chronic renal insufficiency. Hsu CY, McCulloch CE, Curhan GC, J Am Soc Nephrol 2002 13 2783 6 10.1097/01.ASN. 0000034200.82278.DC 12397050 (Pubitemid 35216049)
9. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. Gotloib L, Silverberg D, Fudin R, Shostak A, J Nephrol 2006 19 161 7 16736414 (Pubitemid 44420105)
10. Iron biology in immune function, muscle metabolism and neuronal functioning. Beard JL, J Nutrition 2001 131 568S 580S (Pubitemid 32117681)
11. Iron supplementation in renal anemia. Fishbane S, Semin Nephrol 2006 26 319 324 10.1016/j.semnephrol.2006.05.009 16949471 (Pubitemid 44722452)
12. Clinical aspects of iron use in the anemia of kidney disease. Horl WH, JAm Soc Nephrol 2007 18 382 93 10.1681/ASN.2006080856 (Pubitemid 46193303)
13. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. VanWyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N, Am J Kidney Dis 2000 36 88 97 10.1053/ajkd.2000.8276 10873877 (Pubitemid 30432569)
14. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Walters BA, Van Wyck DB, Nephrol Dial Transplant 2005 20 1438 42 10.1093/ndt/gfh811 15840683 (Pubitemid 41430618)
15. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Agarwal R, Vasavada N, Sachs NG, Chase S, Kidney Int 2004 65 2279 89 10.1111/j.1523-1755.2004.00648.x 15149341 (Pubitemid 38670014)
16. Parenteral iron therapy exacerbates experimental sepsis. Zager RA, Johnson AC, Hanson SY, Kidney Int 2004 65 2108 12 10.1111/j.1523-1755.2004. 00742.x 15149323 (Pubitemid 38669996)
17. Intravenous iron and the risk of infection in end-stage renal disease patients. Brewster UC, Perazella MA, Semin Dial 2004 17 57 60 14717813 (Pubitemid 38376693)
18. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Zager RA, Johnson AC, Hanson SY, Wasse H, Am J Kidney Dis 2002 40 90 103 10.1053/ajkd.2002.33917 12087566 (Pubitemid 34701216)
19. Strategies for iron supplementation: oral versus intravenous. Macdougall IC, Kidney Int 1999 55 Suppl 69 61 6
20. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients [letter]. Nyvad O, Danielsen H, Madsen S, Lancet 1994 344 1305 6 7968018 (Pubitemid 24334711)
21. Intravenous ferric saccharate as an iron supplement in dialysis patients. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A, Nephron 1996 72 413 7 10.1159/000188905 8852489 (Pubitemid 26060802)
22. Clinical practice guidelines for assessment and management of iron deficiency. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Bulleton BF, Tonelli M, Manns BJ, Kidney Int 2008 74 suppl 110 7 11
23. Rationale and design of the oral HEMe iron polypeptide against treatment with oral controlled release iron tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). Barraclough KA, Noble E, Leary D, Brown F, Hawley CM, Campbell SB, Isbel NM, Mudge DW, van Eps CL, Sturtevant JM, Johnson DW, BMC Nephrology 2009 10 20 10.1186/1471-2369-10-20 19635169
24. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Stoves J, Inglis H, Newstead CG, Nephrol Dial Transplant 2001 16 967 74 10.1093/ndt/16.5.967 11328902 (Pubitemid 32440369)
25. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Charytan C, Quinibi W, Bailie GR, Nephron Clin Pract 2005 100 55 c62 10.1159/000085049 15824508 (Pubitemid 40868986)
26. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Aggarwal HK, Nand N, Singh S, Singh M, Hemant Kaushik G, JAssoc Physicians India 2003 51 170 4 (Pubitemid 44227894)
27. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, Kidney Int 2005 68 2846 56 10.1111/j.1523-1755.2005. 00758.x 16316362 (Pubitemid 43251032)
28. Ferumoxytol for treating iron deficiency anemia in CKD. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ, J Am Soc Nephrol 2008 19 1599 605 10.1681/ASN.2007101156 18525001
29. An intestinal receptor for heme. Grasbeck R, Kouvonen I, Lundberg M, Tenhunen R, Scand J Haematol 1979 23 5 9 493872 (Pubitemid 10220627)
30. Absorption of heme iron. Uzel C, Conrad ME, Semin Hematol 1998 35 27 34 9685177 (Pubitemid 28047040)
31. Clinical studies of HIP: an oral heme-iron product. Seligman PA, Moore GM, Schleicher RB, Nutr Res 2000 20 1279 86 10.1016/S0271-5317(00)00215-3
32. Effects of erythropoietin therapy on iron absorption in chronic renal failure. Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD, J Lab Clin Med 2000 135 6 452 8 10.1067/mlc.2000.106807 10850644
33. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Hallberg L, Hulten L, Gramatkovski E, Am J Clin Nutr 1997 66 347 56 9250114 (Pubitemid 27360334)
34. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA, Am J Kidney Dis 2003 42 325 30 10.1016/S0272-6386(03)00658-9 12900815 (Pubitemid 36944441)
35. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A, Am J Nephrol 2006 26 445 54 10.1159/000096174 17035697 (Pubitemid 44971735)
36. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis- dependent chronic kidney disease patients. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD, Nephrol Dial Transplant 2011 26 1599 607 10.1093/ndt/gfq613 20929915
37. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U, Am J Kidney Dis 2008 52 897 906 10.1053/j.ajkd.2008.05.033 18845368
38. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anemia in peritoneal dialysis patients: HEMOATOCRIT trial. Barrraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, Isbel NM, Mudge DW, van Eps CL, John DW, Nephrol Dial Transplant 2012 27 4146 4153 10.1093/ndt/gfs372 22962411
39. A clinical trial of oral versus IV iron in patients with chronic kidney disease http://www.clinicaltrials.gov, clinical trial NCT00830037